SYDNEY, AUSTRALIA, June 08, 2021 (GLOBE NEWSWIRE) – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), the leading developer of LAG-3-related immunotherapy treatments for cancer and autoimmune diseases, is pleased to provide a update on its preclinical development pipeline.
As part of the collaborative project launched in 2019 with Cardiff University, the Company has advanced the discovery and development of a new generation of small molecule anti-LAG-3 therapies. The final objective of the project is to provide cancer patients with oral treatment at a lower cost compared to the anti-LAG-3 antibodies currently being developed by several companies.
The project brings together Immutep’s in-depth experience in LAG-3 biology, with the expertise of Cardiff University professors Andrew Godkin and Andrea Brancale. Professor Godkin is the Academic Theme Leader in Immunology at the College of Biomedical Life Sciences and Professor Brancale is Professor of Medicinal Chemistry in the Faculty of Pharmacy and Pharmaceutical Sciences.
“Never has there been a more exciting time to explore new ideas for controlling the interaction between LAG-3 and MHC class II molecules, following the recent validation of LAG-3 by the pharmaceutical industry. We are delighted to advance this project with the world’s leading scientists at Cardiff University and to continue our work to develop new LAG-3 therapies, especially as our joint efforts have already achieved exciting first results ”, said Marc Voigt, CEO of Immutep.
“We are delighted to be working with Immutep on this important project to develop a small molecule anti-LAG-3 treatment for cancer patients that could offer the convenience of a tablet or capsule, at a fraction of the cost. existing anti-LAG-3s. candidates, ”said Professor Andrew Godkin of Cardiff University.
Cardiff University Professor Andrea Brancale also added: “Our collaboration with Immutep is a great opportunity to combine a diverse set of skills from multiple teams in what is an exciting area of research. Indeed, we believe that this transversal expertise in chemistry, biology and drug development positions the team very well for a successful collaboration.
Under the agreement, all intellectual property relating to the lead compounds and their derivatives will be jointly owned by Immutep and Cardiff University. Immutep will have the exclusive rights to develop and market the new molecules in the clinic under predefined license conditions. The agreement is based on a material transfer agreement signed by Immutep SAS and Cardiff University in 2015.
“Our collaboration with Cardiff University demonstrates our commitment to continually invest in R&D. We believe that the findings resulting from this collaboration and our collaboration with Monash University may have a profound impact on the LAG-3 landscape, particularly with regard to anti-LAG-3 therapies currently in late stages of development ” , said Immutep and CMO CSO, Dr Frédéric Triebel.
As announced on August 31, 2020, the Australian Research Council (ARC) has awarded Immutep and its research partner Monash University a grant under the ARC Linkage Project to support their research collaboration in the LAG- 3 for a further period of three years. The Monash University research team for the project is led by Prof. Jamie Rossjohn, ARC Laureate Fellow at Monash Biomedicine Discovery Institute and Professor of Structural Immunology at Cardiff University.
About Cardiff University
Cardiff University is a UK university in the Russell Group and has been ranked in the top five universities in the latest UK government research exercises. This collaborative project with Immutep is carried out within the Faculty of Medicine and the Faculty of Pharmacy of the College of Biomedical Life Sciences. There is a strong interest in basic and translational biomedical sciences at the University, which fits well with this collaboration. Professor Andrea Brancale is an internationally renowned expert in medicinal chemistry, and Professor Andrew Godkin runs a laboratory in the Henry Wellcome building of the Faculty of Medicine, specializing in basic and translational immunology of cancer.
Immutep is a globally active biotechnology company, a leader in the development of immunotherapeutics related to LAG-3 for the treatment of cancer and autoimmune diseases. Immutep is committed to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value. Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.
Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-class antigen-presenting cell (APC) activator currently being explored in the world. cancer and infectious diseases. Immutep is also developing an LAG-3 agonist (IMP761) for autoimmune diseases. Other LAG-3 products, including antibodies for modulating the immune response, are under development by Immutep’s major pharmaceutical partners.
Further information can be found on the company’s website www.immutep.com or by contacting:
Australian Investors / Media:
Catherine Strong, Citadelle-MAGNUS
+61 (0) 406 759 268; [email protected]
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]